This study compares a medication called maridebart cafraglutide with a placebo (a harmless pill) to see if it helps adults with obstructive sleep apnea (OSA), a condition where breathing stops and starts during sleep. This trial lasts for 52 weeks, and is for people who are overweight or obese and not using a machine called Positive Airway Pressure (PAP), which helps people with OSA breathe at night. To join, participants need to have an Apnea-Hypopnea Index (AHI) of 15 or higher. The AHI shows how many times breathing stops per hour during sleep. They also need a Body Mass Index (BMI) of at least 27, which is a measure of body fat based on height and weight.

• This study takes 52 weeks to complete.
• Participants must not use PAP therapy during the study.
• Participants should have tried and failed to lose weight through diet and exercise before.